Han Xiudan, Long Wei, Liu Ying, Xu Jixiong
Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, China.
Jiangxi Clinical Research Center for Endocrine and Metabolic Disease, Nanchang, China.
Front Surg. 2022 Oct 21;9:985034. doi: 10.3389/fsurg.2022.985034. eCollection 2022.
In recent years, the role of BAI1-associated protein 2-like 2 (BAIAP2L2) in the prognosis and immune microenvironment of various cancers has attracted increasing attention. However, its clinical value and immune infiltration in liver hepatocellular carcinoma (LIHC) remain unclear.
To investigate the prognostic value of BAIAP2L2 and its correlation with immune infiltration in LIHC, we conducted corresponding data mining.
In this study, The Cancer Genome Atlas, GTEx, StarBase, UALCAN, TIMER, GEPIA, Human Protein Atlas, Kaplan-Meier Plotter, cBioPortal, LinkedOmics, STRING and BioGPS databases were used to analyze BAIAP2L2 in cancers. Logistic regression and Cox regression were performed to analyze the correlation between clinical features and BAIAP2L2 expression in LIHC. In addition, the diagnostic and prognostic values of BAIAP2L2 in LIHC were determined by receiver operating characteristic (ROC) curves and nomograms. Single-sample gene set enrichment analysis (ssGSEA), BioGPS and TIMER were used to analyze the correlation between BAIAP2L2 and immune infiltration. More importantly, quantitative real-time polymerase chain reaction was used to verify BAIAP2L2 expression in a liver cancer cell line and a normal cell line. Visualization of data was mostly achieved using R language, version 3.6.3.
High BAIAP2L2 levels indicated poor overall survival (OS) and disease-free survival (DFS) of patients with LIHC. Abnormally increased expression of BAIAP2L2 in LIHC may be the result of both genetic alterations and lower DNA methylation levels. Furthermore, Cox regression analysis showed that high BAIAP2L2 expression was an independent risk factor for OS and DFS in patients with liver cancer. ROC curves and nomograms also confirmed the diagnostic and prognostic values of BAIAP2L2 in LIHC. Additionally, a PPI network of BAIAP2L2 was established and results implyed that BAIAP2L2 interacts with MTSS1, AMPH, FCHO1, SYT9, PDK2, MTSS1L, PM20D1, CHST4 and PALM3. ssGSEA showed that BAIAP2L2 was associated with T cells and natural killer cells. Simultaneously, the TIMER database showed that the expression of BAIAP2L2 in LIHC was positively correlated with tumor infiltrating cells, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells.
Through pan-cancer analysis, prognostic and immunological value of BAIAP2L2 in LIHC was identified. This is the first report on the potential of BAIAP2L2 as a prognostic biomarker and its correlation with immune infiltration in LIHC.
近年来，BAI1相关蛋白2样蛋白2（BAIAP2L2）在各种癌症的预后和免疫微环境中的作用受到越来越多的关注。然而，其在肝细胞癌（LIHC）中的临床价值和免疫浸润情况仍不清楚。
为了研究BAIAP2L2在LIHC中的预后价值及其与免疫浸润的相关性，我们进行了相应的数据挖掘。
在本研究中，使用了癌症基因组图谱（The Cancer Genome Atlas）、GTEx、StarBase、UALCAN、TIMER、GEPIA、人类蛋白质图谱（Human Protein Atlas）、Kaplan-Meier Plotter、cBioPortal、LinkedOmics、STRING和BioGPS数据库来分析癌症中的BAIAP2L2。进行逻辑回归和Cox回归分析以分析LIHC中临床特征与BAIAP2L2表达之间的相关性。此外，通过受试者工作特征（ROC）曲线和列线图确定BAIAP2L2在LIHC中的诊断和预后价值。使用单样本基因集富集分析（ssGSEA）、BioGPS和TIMER来分析BAIAP2L2与免疫浸润之间的相关性。更重要的是，使用定量实时聚合酶链反应来验证BAIAP2L2在肝癌细胞系和正常细胞系中的表达。数据可视化大多使用R语言3.6.3版本完成。
BAIAP2L水平高表明LIHC患者的总生存期（OS）和无病生存期（DFS）较差。LIHC中BAIAP2L2表达异常增加可能是基因改变和DNA甲基化水平降低共同作用的结果。此外，Cox回归分析表明，BAIAP2L2高表达是肝癌患者OS和DFS的独立危险因素。ROC曲线和列线图也证实了BAIAP2L2在LIHC中的诊断和预后价值。此外，建立了BAIAP2L2的蛋白质-蛋白质相互作用（PPI）网络，结果表明BAIAP2L2与MTSS1、AMPH、FCHO1、SYT9、PDK2、MTSS1L、PM20D1、CHST4和PALM3相互作用。ssGSEA表明BAIAP2L2与T细胞和自然杀伤细胞有关。同时，TIMER数据库显示，BAIAP2L2在LIHC中的表达与肿瘤浸润细胞呈正相关，包括B细胞、CD8 + T细胞、CD4 + T细胞、巨噬细胞、中性粒细胞和树突状细胞。
通过泛癌分析，确定了BAIAP2L2在LIHC中的预后和免疫价值。这是关于BAIAP2L2作为预后生物标志物的潜力及其与LIHC免疫浸润相关性的首次报道。
